Pharmacovigilance Market Investment Opportunities 2024-2032
The Pharmacovigilance Market was valued at USD 6.73 billion in 2022 and is projected to reach USD 17.13 billion by 2030, growing at a CAGR of 12.5% over the forecast period. As global healthcare systems expand and regulatory standards tighten, the demand for robust pharmacovigilance systems continues to grow. The Pharmacovigilance Market Size reflects the rising importance of drug safety monitoring in the life sciences industry.
The increasing incidence of adverse drug reactions (ADRs), coupled with stricter government regulations and rising pharmaceutical R&D activities, is fueling market expansion. Pharmaceutical companies are increasingly investing in automated pharmacovigilance technologies, including artificial intelligence and machine learning, to ensure compliance and enhance drug safety outcomes.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/3095
Key Players:
ArisGlobal, Cognizant, IBM, Clinquest Group B.V. (Linical Americas), Accenture, Laboratory Corporation of America Holdings, IQVIA, Capgemini, ICON plc., ITClinical, ClinChoice (formerly FMD K&L), TAKE Solutions Limited, Wipro, Parexel International (MA) Corporation, BioClinica Inc. (Clario), United BioSource LLC and others.
Key Points:
- Market valuation reached USD 6.73 billion in 2022, projected to hit USD 17.13 billion by 2030
- CAGR of 12.5% expected during the 2023–2030 forecast period
- Rising cases of adverse drug reactions (ADRs) are a key growth driver
- Growing adoption of AI and automation in drug safety monitoring
- Pharmaceutical outsourcing trends boosting demand for third-party PV services
- Stringent regulatory frameworks pushing for enhanced vigilance systems
- Post-marketing surveillance remains a dominant segment
- North America holds the largest market share, followed by Europe and Asia-Pacific
Future Scope:
The pharmacovigilance industry is expected to undergo transformative changes with the increasing integration of digital technologies. Future growth will be driven by real-time data analysis, wearable device monitoring, and predictive safety modeling. Emerging markets, especially in Asia-Pacific and Latin America, present lucrative opportunities as governments enhance regulatory infrastructure and local pharmaceutical industries expand. As personalized medicine and biologics gain prominence, the scope of pharmacovigilance will also extend to niche therapies, further broadening its global footprint.
Conclusion:
The pharmacovigilance market is entering a dynamic growth phase, propelled by regulatory scrutiny, technological innovation, and the pharmaceutical sector’s heightened focus on patient safety. Stakeholders across the drug development value chain must adapt to evolving compliance requirements while leveraging data-driven tools to optimize safety assessments. The market outlook remains robust, with sustained demand forecast across regions and therapeutic areas.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
Comments
0 comment